arrow
S

Stergios Kechagias

Linköping University
H指数:43
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prevalence and Significance of Combined Low Muscle Volume and High Muscle Fat in Patients with Child–Pugh A-B Cirrhosis

Child–Pugh A-B级肝硬化患者中低肌肉量和肌肉脂肪含量升高的患病率及意义

2026-09-110
OAAI
Chronic Liver Disease: Assessing Inflammation and Fibrosis Using Three-Dimensional MR Elastography With Same-Day Biopsy in a Prospective Cohort

慢性肝病:使用三维磁共振弹性成像结合同日活检评估炎症和纤维化,前瞻性队列研究

2026-04-020
OA
Validity of the International Fitness Scale (IFIS) and its associations with cardiometabolic health and body composition in adults with type 2 diabetes: A cross-sectional study

国际健身量表(IFIS)的有效性及其与2型糖尿病成人代谢健康和身体成分的关联:一项横断面研究

2026-01-060
PRE
Reply: Competing risk and surveillance thresholds for HCC in patients with PSC

回复:PSC患者中HCC的竞争风险与监测阈值

2025-12-010
PRE
Comparison of liver histology and fibrosis-4 scoring as tools for evaluating healthcare resource utilization and costs in patients with MASLD: a Swedish cohort study

比较肝组织学与纤维化-4评分作为评估MASLD患者医疗资源利用和成本的工具:一项瑞典队列研究

2025-09-011
OA
Effect of Hypertension on Long-term Adverse Clinical Outcomes and Liver Fibrosis Progression in MASLD

高血压对长期不良临床结局及MASLD患者肝纤维化进展的影响

2025-08-230
PRE
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD

纤维化标志物的纵向变化:监测MASLD的僵硬/纤维化进展和预后结局

2025-07-240
PRE
Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care

评估2型糖尿病患者在初级保健中代谢功能障碍相关脂肪性肝病的患病率和严重程度

2025-06-160
OAAI
The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease
2025-02-010
PRE